The protective efficacy of polyvalent pneumococcal polysaccharide vaccine - PubMed (original) (raw)
Clinical Trial
. 1991 Nov 21;325(21):1453-60.
doi: 10.1056/NEJM199111213252101.
Affiliations
- PMID: 1944423
- DOI: 10.1056/NEJM199111213252101
Free article
Clinical Trial
The protective efficacy of polyvalent pneumococcal polysaccharide vaccine
E D Shapiro et al. N Engl J Med. 1991.
Free article
Abstract
Background: Although the protective efficacy of pneumococcal polysaccharide vaccine has been demonstrated in randomized trials in young African gold miners, there has been controversy about its efficacy in older Americans at risk for serious pneumococcal infections. To assess the vaccine's protective efficacy against invasive pneumococcal infections, we conducted a hospital-based case-control study of the efficacy of pneumococcal vaccine in adults with a condition recognized to be an indication for receiving the vaccine.
Methods: From 1984 to 1990, adults in whom Streptococcus pneumoniae was isolated from any normally sterile site were identified by prospective surveillance in the microbiology laboratories of 11 large hospitals; those with an indication for pneumococcal vaccine were enrolled as case patients. For each case patient, one control was matched according to age, underlying illness, and site of hospitalization. We contacted all providers of medical care to ascertain each subject's history of immunization with pneumococcal vaccine. Isolates of S. pneumoniae were serotyped by an investigator unaware of the subject's vaccination history.
Results: Thirteen percent of the 1,054 case patients and 20 percent of the 1,054 matched controls had received pneumococcal vaccine (P less than 0.001). When vaccine was given in either its 14-valent or its 23-valent form, its aggregate protective efficacy (calculated as a percentage: 1 minus the odds ratio of having been vaccinated times 100) against infections caused by the serotypes represented in the vaccine was 56 percent (95 percent confidence interval, 42 percent to 67 percent; P less than 0.00001) for all 983 patients infected with a serotype represented in the vaccine, 61 percent for a subgroup of 808 immunocompetent patients (95 percent confidence interval, 47 percent to 72 percent; P less than 0.00001), and 21 percent for a subgroup of 175 immunocompromised patients (95 percent confidence interval, -55 percent to 60 percent; P = 0.48). The vaccine was not efficacious against infections caused by serotypes not represented in the vaccine (protective efficacy, -73 percent; 95 percent confidence interval, -263 percent to 18 percent; P = 0.15).
Conclusions: Polyvalent pneumococcal vaccine is efficacious in preventing invasive pneumococcal infections in immunocompetent patients with indications for its administration. This vaccine should be used more widely.
Comment in
- Pneumococcal vaccine--past, present, and future.
Broome CV, Breiman RF. Broome CV, et al. N Engl J Med. 1991 Nov 21;325(21):1506-8. doi: 10.1056/NEJM199111213252109. N Engl J Med. 1991. PMID: 1944428 Clinical Trial. No abstract available.
Similar articles
- A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection.
Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N; Vaccine Trialists Group. Klugman KP, et al. N Engl J Med. 2003 Oct 2;349(14):1341-8. doi: 10.1056/NEJMoa035060. N Engl J Med. 2003. PMID: 14523142 Clinical Trial. - Preventing pneumococcal bacteremia in patients at risk. Results of a matched case-control study.
Farr BM, Johnston BL, Cobb DK, Fisch MJ, Germanson TP, Adal KA, Anglim AM. Farr BM, et al. Arch Intern Med. 1995 Nov 27;155(21):2336-40. Arch Intern Med. 1995. PMID: 7487259 - Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine.
Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, Reingold A, Cieslak PR, Pilishvili T, Jackson D, Facklam RR, Jorgensen JH, Schuchat A; Active Bacterial Core Surveillance of the Emerging Infections Program Network. Whitney CG, et al. N Engl J Med. 2003 May 1;348(18):1737-46. doi: 10.1056/NEJMoa022823. N Engl J Med. 2003. PMID: 12724479 - Pneumococcal vaccine.
LaForce FM. LaForce FM. Semin Respir Infect. 1989 Dec;4(4):293-8. Semin Respir Infect. 1989. PMID: 2697052 Review. - Adult pneumococcal vaccination guideline. SAMA-SA Pulmonology Society Working Group.
[No authors listed] [No authors listed] S Afr Med J. 1999 Nov;89(11 Suppl):1222-30. S Afr Med J. 1999. PMID: 10599303 Review.
Cited by
- Influenza Vaccine Effectiveness and Progress Towards a Universal Influenza Vaccine.
Cowling BJ, Okoli GN. Cowling BJ, et al. Drugs. 2024 Sep;84(9):1013-1023. doi: 10.1007/s40265-024-02083-8. Epub 2024 Aug 21. Drugs. 2024. PMID: 39167316 Free PMC article. Review. - Protective Effects from Prior Pneumococcal Vaccination in Patients with Chronic Airway Diseases during Hospitalization for Influenza-A Territory-Wide Study.
Kwok WC, Lung DC, Tam TC, Yap DY, Ma TF, Tsui CK, Zhang R, Lam DC, Ip MS, Ho JC. Kwok WC, et al. Vaccines (Basel). 2024 Jun 23;12(7):704. doi: 10.3390/vaccines12070704. Vaccines (Basel). 2024. PMID: 39066342 Free PMC article. - Follow-Up Study of Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine Against All-Type and Serotype-Specific Invasive Pneumococcal Disease, Denmark.
Nielsen KF, Nielsen LB, Dalby T, Lomholt FK, Slotved HC, Fuursted K, Harboe ZB, Jørgensen CS, Valentiner-Branth P. Nielsen KF, et al. Emerg Infect Dis. 2024 Jun;30(6):1164-1172. doi: 10.3201/eid3006.230975. Emerg Infect Dis. 2024. PMID: 38781925 Free PMC article. - Diabetes as a risk factor for pneumococcal disease and severe related outcomes and efficacy/effectiveness of vaccination in diabetic population. Results from meta-analysis of observational studies.
Silverii GA, Gabutti G, Tafuri S, Sarti F, Pratesi A, Clerico A, Fornengo R, Greco C, Irace C, Sordi V, Sorice GP, Cavallo M, Ponziani MC, Mannucci E, Dicembrini I; SID-AMD-SItI Working Group on Diabetes, Vaccines. Silverii GA, et al. Acta Diabetol. 2024 Aug;61(8):1029-1039. doi: 10.1007/s00592-024-02282-5. Epub 2024 Apr 29. Acta Diabetol. 2024. PMID: 38684540 Free PMC article. - [Guidelines for the management of community pneumonia in adult who needs hospitalization].
Álvarez-Rocha L, Alós JI, Blanquer J, Álvarez-Lerma F, Garau J, Guerrero A, Torres A, Cobo J, Jordá R, Menéndez R, Olaechea P, Rodríguez de Castro F; Grupo de Estudio de la Neumonía Comunitaria Grave. Álvarez-Rocha L, et al. Med Intensiva. 2005 Feb;29(1):21-62. doi: 10.1016/S0210-5691(05)74199-1. Epub 2009 Jan 6. Med Intensiva. 2005. PMID: 38620135 Free PMC article. Spanish.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources